No connection

Search Results

NOTV

BEARISH
$0.24 Live
Inotiv, Inc. · NASDAQ
Target $3.25 (+1226.5%)
$0.22 52W Range $3.32

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 15, 2026
Market cap
$8.43M
P/E
N/A
ROE
-49.8%
Profit margin
-13.5%
Debt/Equity
4.37
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
NOTV exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.30 and a Quick Ratio of 0.17, suggesting it cannot meet its short-term obligations. High leverage (Debt/Equity of 4.37) combined with stagnant revenue growth (0.80%) and consistent earnings misses creates a high risk of insolvency. The catastrophic 5-year price decline of 98.8% and bearish insider activity further confirm a negative outlook.

Key Strengths

Positive Gross Margin (23.49%)
Extremely low Price-to-Sales ratio (0.02)
Extremely low Price-to-Book ratio (0.08)
Positive revenue growth (though marginal at 0.80%)
Presence of analyst coverage despite micro-cap status

Key Risks

Severe liquidity risk (Current Ratio 0.30)
Excessive leverage (Debt/Equity 4.37)
Consistent failure to meet earnings estimates (0/4 beats)
Heavy insider selling by CEO and CFO
Extreme price volatility and long-term value destruction (-98.8% 5Y)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
20
Future
15
Past
5
Health
10
Dividend
0
AI Verdict
High Risk of Insolvency
Key drivers: Critical liquidity shortage, Fundamental health collapse (Piotroski 1/9), Negative earnings trajectory, Bearish insider sentiment
Confidence
90%
Value
20/100

P/E is N/A; Graham Number cannot be calculated due to negative earnings.

Positives
  • P/S of 0.02
  • P/B of 0.08
Watchpoints
  • Metrics reflect a 'value trap' rather than a bargain
  • Lack of earnings to support valuation
Future
15/100

Revenue growth is stagnant at 0.80%, failing to offset operating losses.

Positives
  • Marginal YoY revenue growth
Watchpoints
  • Q/Q EPS growth of -295.2%
  • Consistent earnings misses
Past
5/100

Long-term trend is a near-total loss of shareholder value.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -98.8%
  • 1Y Change: -84.2%
Health
10/100

Severe distress; Altman Z-Score not provided but liquidity ratios signal imminent risk.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 1/9
  • Debt/Equity 4.37
  • Current Ratio 0.30
Dividend
0/100

Dividend Yield: N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.24
Analyst Target
$3.25
Upside/Downside
+1226.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for NOTV and closest competitors.

Updated 2026-04-14
NOT
Inotiv, Inc.
Primary
5Y
-98.8%
3Y
-95.0%
1Y
-84.2%
6M
-82.6%
1M
-31.9%
1W
-2.0%
GEL
Gelteq Limited
Peer
5Y
-73.9%
3Y
-73.9%
1Y
-14.8%
6M
-43.5%
1M
+3.7%
1W
+13.2%
IMR
Immuron Limited
Peer
5Y
-85.9%
3Y
-59.6%
1Y
-51.9%
6M
-61.7%
1M
-3.3%
1W
-1.0%
EVG
Evogene Ltd.
Peer
5Y
-98.3%
3Y
-86.8%
1Y
-23.5%
6M
-45.0%
1M
+5.7%
1W
-0.8%
ALU
Allurion Technologies Inc.
Peer
5Y
-99.8%
3Y
-99.8%
1Y
-84.6%
6M
-75.5%
1M
-69.7%
1W
-11.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-4.9
PEG Ratio
N/A
P/B Ratio
0.08
P/S Ratio
0.02
EV/Revenue
0.92
EV/EBITDA
26.68
Market Cap
$8.43M

Profitability

Profit margins and return metrics

Profit Margin -13.5%
Operating Margin -13.36%
Gross Margin 23.49%
ROE -49.76%
ROA -3.14%

Growth

Revenue and earnings growth rates

Revenue Growth +0.8%
Earnings Growth N/A
Q/Q Revenue Growth +0.84%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
4.37
High debt
Current Ratio
0.3
Weak
Quick Ratio
0.17
Poor
Cash/Share
$0.37

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.1B
Gross Margin
20.5%
Op. Margin
-13.4%
Net Margin
-23.5%
Total Assets
$0.7B
Liabilities
$0.6B
Equity
$0.1B
Debt/Equity
5.74x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
195%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06
$N/A
2026-02-09
$-0.83
-29.7% surprise
2025-12-03
$-0.21
-157.5% surprise
2025-08-06
$-0.48
-217.3% surprise

Healthcare Sector Comparison

Comparing NOTV against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-49.76%
This Stock
vs
-101.52%
Sector Avg
-51.0% (Below Avg)
Profit Margin
-13.5%
This Stock
vs
-12.47%
Sector Avg
+8.2% (Better)
Debt to Equity
4.37
This Stock
vs
3.4
Sector Avg
+28.4% (Higher)
Revenue Growth
0.8%
This Stock
vs
124.21%
Sector Avg
-99.4% (Slower)
Current Ratio
0.3
This Stock
vs
4.56
Sector Avg
-93.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

TAYLOR BETH A
Chief Financial Officer
Sell
2026-02-17
2,888 shares · $846
SAGARTZ JOHN E
Officer
Sell
2026-02-17
2,119 shares · $616
LEASURE ROBERT JR.
Chief Executive Officer
Sell
2026-02-17
16,810 shares · $4,964
LEASURE ROBERT JR.
Chief Executive Officer
Sell
2026-02-02
113,297 shares · $57,034
NEFF R MATTHEW
Director
Sell
2025-12-01
2,000 shares · $1,771
NEFF R MATTHEW
Director
Sell
2025-11-03
2,000 shares · $2,487
NEFF R MATTHEW
Director
Option Exercise
2025-10-24
10,000 shares · $19,400
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
2 analysts
Lake Street
2026-02-10
Maintains
Buy Buy
Lake Street
2025-12-04
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning NOTV from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile